Recent Updates
Recently added Catalysts
KYMR Positive Sentiment

Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026

Key Takeaway: Kymera Therapeutics plans to announce results from its BROADEN2 Phase 2b trial for KT-621 on November 23, 2026. This investigational oral STAT6 degrader targets moderate to severe atopic dermatitis. The company will issue a press release at 7:00 a.m. ET, followed by a video conference call at 8:00 a.m. ET.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kymera will announce Phase 2b trial results soon.
  • KT-621 is a first-in-class oral treatment for atopic dermatitis.
  • The drug targets Type 2 inflammation effectively.
  • Kymera is recognized as a top workplace in Boston.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+95%
120-day peak, hindsight
Typical move
9.4%
average across 15 past catalysts
Cash runway
~63 mo
Minimal dilution risk
Lead asset
KT-621
Phase 2 · Eosinophilic Asthma

Full Press Release Details

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026
WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event.
About KT-621 KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in clinical development in AD and asthma. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for millions of patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.
About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: Justine Koenigsberg investors@kymeratx.com 857-285-5300

Media Contact: Matthew Henson media@kymeratx.com 857-285-5300

Frequently Asked Questions

What is KT-621?

KT-621 is an investigational oral STAT6 degrader for treating atopic dermatitis.

When will the trial results be announced?

Results will be announced on November 23, 2026.

How can I join the webcast?

Register via the link on Kymera's website to join the webcast.

What diseases does KT-621 target?

KT-621 targets atopic dermatitis and other Type 2 inflammatory diseases.

Last updated: Nov 20, 2026